首页 > 最新文献

Annals of Pediatric Endocrinology & Metabolism最新文献

英文 中文
Central precocious puberty: is routine brain MRI screening necessary for girls?: Commentary on "Brain magnetic resonance imaging (MRI) findings in central precocious puberty patients: is routine MRI necessary for newly diagnosed patients?" 中枢性早熟:女孩是否需要进行常规的脑部核磁共振检查?:“中枢性早熟患者的脑磁共振成像(MRI)结果:新诊断患者是否需要常规MRI?”
IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 Epub Date: 2023-09-19 DOI: 10.6065/apem.2322096edi07
Hae Sang Lee
©2023 Annals of Pediatric Endocrinology & Metabolism This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ISSN: 2287-1012(Print) ISSN: 2287-1292(Online) Central precocious puberty (CPP) is defined by the early activation of hypothalamicpituitary-gonadal axis before the age of 8 years in girls and 9 years in boys. With a ratio of 1:5 to 1:10, precocious puberty is more common in girls than in boys. The onset of puberty is a multifaceted phenomenon influenced by a combination of genetic and environmental factors, including factors such as obesity and endocrine disruptors. In addition, the onset of typical puberty shows individual variability and is determined by a variety of genetic factors, including both rare and common variations. Approximately 90% to 95% of girls have idiopathic form of CPP, but approximately 40% to 75% of boys with CPP have pathological brain lesions, including hypothalamic hamartoma, pituitary adenoma, and germinoma. Therefore, magnetic resonance imaging (MRI) of the brain can be performed to evaluate children with CPP and rule out the possibility of pathological brain lesions. In global consensus statement on CPP, all boys with CPP and girls younger than 6 years of age with CPP should undergo a brain MRI as a part of etiological investigation. However, there is controversy as to whether brain MRI should be performed on girls with precocious puberty between the ages of 6 and 8. The numerous studies have investigated the prevalence and types of intracranial lesions in CPP cases, as well as the benefit of brain MRI in girls with age at puberty onset older than 6 years without neurological abnormality. Yoon et al. reported that when brain MRI was performed on girls diagnosed with precocious puberty at an average age of 6.8 years, 91.8% showed normal findings. Also, any pathological lesions among girls with CPP were not detected. In recent systematic review, the prevalence of brain lesions in patients with CPP was 12% in girls younger than 7 years old and only 3% in girls between 7–8 years old. In a recent study by Oh et al., a pathological brain lesion which was diagnosed as hypothalamic hamartoma was only detected in one girl (6.1 years of age) out 199 girls with CPP. The detection rate of brain lesions not only in girls but also in boys is not higher in recent studies compared to previous literature. Out of 138 boys with CPP who underwent brain MRI, brain lesions including pituitary hyperplasia, thickening of the pituitary stalk, and Rathke cleft cyst were found in 10 boys (7%). Oh et al. reported that 4 of 24 boys (16.6%) with CPP had pituitary abnormalities, but no pathological brain lesions were not observed. Recent westernized eating habits and the increase in obesity are th
{"title":"Central precocious puberty: is routine brain MRI screening necessary for girls?: Commentary on \"Brain magnetic resonance imaging (MRI) findings in central precocious puberty patients: is routine MRI necessary for newly diagnosed patients?\"","authors":"Hae Sang Lee","doi":"10.6065/apem.2322096edi07","DOIUrl":"10.6065/apem.2322096edi07","url":null,"abstract":"©2023 Annals of Pediatric Endocrinology & Metabolism This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ISSN: 2287-1012(Print) ISSN: 2287-1292(Online) Central precocious puberty (CPP) is defined by the early activation of hypothalamicpituitary-gonadal axis before the age of 8 years in girls and 9 years in boys. With a ratio of 1:5 to 1:10, precocious puberty is more common in girls than in boys. The onset of puberty is a multifaceted phenomenon influenced by a combination of genetic and environmental factors, including factors such as obesity and endocrine disruptors. In addition, the onset of typical puberty shows individual variability and is determined by a variety of genetic factors, including both rare and common variations. Approximately 90% to 95% of girls have idiopathic form of CPP, but approximately 40% to 75% of boys with CPP have pathological brain lesions, including hypothalamic hamartoma, pituitary adenoma, and germinoma. Therefore, magnetic resonance imaging (MRI) of the brain can be performed to evaluate children with CPP and rule out the possibility of pathological brain lesions. In global consensus statement on CPP, all boys with CPP and girls younger than 6 years of age with CPP should undergo a brain MRI as a part of etiological investigation. However, there is controversy as to whether brain MRI should be performed on girls with precocious puberty between the ages of 6 and 8. The numerous studies have investigated the prevalence and types of intracranial lesions in CPP cases, as well as the benefit of brain MRI in girls with age at puberty onset older than 6 years without neurological abnormality. Yoon et al. reported that when brain MRI was performed on girls diagnosed with precocious puberty at an average age of 6.8 years, 91.8% showed normal findings. Also, any pathological lesions among girls with CPP were not detected. In recent systematic review, the prevalence of brain lesions in patients with CPP was 12% in girls younger than 7 years old and only 3% in girls between 7–8 years old. In a recent study by Oh et al., a pathological brain lesion which was diagnosed as hypothalamic hamartoma was only detected in one girl (6.1 years of age) out 199 girls with CPP. The detection rate of brain lesions not only in girls but also in boys is not higher in recent studies compared to previous literature. Out of 138 boys with CPP who underwent brain MRI, brain lesions including pituitary hyperplasia, thickening of the pituitary stalk, and Rathke cleft cyst were found in 10 boys (7%). Oh et al. reported that 4 of 24 boys (16.6%) with CPP had pituitary abnormalities, but no pathological brain lesions were not observed. Recent westernized eating habits and the increase in obesity are th","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"28 3","pages":"155-156"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/4e/apem-2322096edi07.PMC10556437.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41153033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New-onset type 1 diabetes mellitus in the Paediatric Emergency Department: impact of the COVID-19 pandemic. 儿科急诊科的新发1型糖尿病:新冠肺炎大流行的影响。
IF 2.8 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 Epub Date: 2023-09-19 DOI: 10.6065/apem.2346088.044
Raquel García Romero, Laia Baleta Riera, Nuria Sanz Marcos, Vanessa Arias Constanti, Victoria Trenchs Sainz de la Maza, Carles Luaces

Purpose: On the 14th of March 2020, the Spanish government decreed a state of alarm due to the coronavirus disease 2019 (COVID-19) pandemic, directly affecting healthcare. This situation led to delayed diagnosis of several serious diseases, and its impact on many diseases such as the onset of type 1 diabetes mellitus (T1DM) remains unknown. The aim of this study is to determine the impact of the COVID-19 pandemic on the onset of T1DM in children.

Methods: A descriptive-observational study was performed using data from children younger than 18 years (n=115) admitted with diagnosis of T1DM. We compared the 8 months from May-December 2020 to the same timeframe in 2019.

Results: Our data show an increase of newly attended cases of T1DM in 2020, due to referral of Catalan children with onset of diabetes to our centre. Moreover, fewer patients presented with simple hyperglycaemia at the onset of the COVID-19 period. Delay in consulting the hospital, decreased access to the healthcare system, and avoidance of hospitals to minimize exposure to COVID-19 could have contributed to this finding. There were no differences in the number of days of hospitalization (including days in the paediatric intensive care uniy) between the years.

Conclusion: The effects of the lockdown during the COVID-19 pandemic not only delayed the diagnosis of diabetes, but also its allowed time for its severity to increase. Future studies should focus on the influence of new variants of COVID-19 on the onset of T1DM during the postvaccination period.

目的:2020年3月14日,西班牙政府因2019冠状病毒病(新冠肺炎)大流行而下令进入警报状态,直接影响医疗保健。这种情况导致了几种严重疾病的诊断延迟,其对许多疾病的影响,如1型糖尿病(T1DM)的发病仍然未知。本研究的目的是确定新冠肺炎大流行对儿童T1DM发病的影响。方法:使用诊断为T1DM的18岁以下儿童(n=115)的数据进行描述性观察性研究。我们将2020年5月至12月的8个月与2019年同期进行了比较。结果:我们的数据显示,由于加泰罗尼亚糖尿病儿童被转诊到我们的中心,2020年新就诊的T1DM病例有所增加。此外,新冠肺炎发病时出现单纯高血糖的患者较少。咨询医院的延迟、进入医疗系统的机会减少,以及为了尽量减少接触新冠肺炎而避开医院,都可能是这一发现的原因。住院天数(包括在儿科重症监护病房的天数)在不同年份之间没有差异。结论:新冠肺炎大流行期间封锁的影响不仅推迟了糖尿病的诊断,而且也为其严重程度的增加留出了时间。未来的研究应重点关注新冠肺炎新变种对疫苗接种后T1DM发病的影响。
{"title":"New-onset type 1 diabetes mellitus in the Paediatric Emergency Department: impact of the COVID-19 pandemic.","authors":"Raquel García Romero, Laia Baleta Riera, Nuria Sanz Marcos, Vanessa Arias Constanti, Victoria Trenchs Sainz de la Maza, Carles Luaces","doi":"10.6065/apem.2346088.044","DOIUrl":"10.6065/apem.2346088.044","url":null,"abstract":"<p><strong>Purpose: </strong>On the 14th of March 2020, the Spanish government decreed a state of alarm due to the coronavirus disease 2019 (COVID-19) pandemic, directly affecting healthcare. This situation led to delayed diagnosis of several serious diseases, and its impact on many diseases such as the onset of type 1 diabetes mellitus (T1DM) remains unknown. The aim of this study is to determine the impact of the COVID-19 pandemic on the onset of T1DM in children.</p><p><strong>Methods: </strong>A descriptive-observational study was performed using data from children younger than 18 years (n=115) admitted with diagnosis of T1DM. We compared the 8 months from May-December 2020 to the same timeframe in 2019.</p><p><strong>Results: </strong>Our data show an increase of newly attended cases of T1DM in 2020, due to referral of Catalan children with onset of diabetes to our centre. Moreover, fewer patients presented with simple hyperglycaemia at the onset of the COVID-19 period. Delay in consulting the hospital, decreased access to the healthcare system, and avoidance of hospitals to minimize exposure to COVID-19 could have contributed to this finding. There were no differences in the number of days of hospitalization (including days in the paediatric intensive care uniy) between the years.</p><p><strong>Conclusion: </strong>The effects of the lockdown during the COVID-19 pandemic not only delayed the diagnosis of diabetes, but also its allowed time for its severity to increase. Future studies should focus on the influence of new variants of COVID-19 on the onset of T1DM during the postvaccination period.</p>","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"28 3","pages":"215-218"},"PeriodicalIF":2.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/45/apem-2346088-044.PMC10556438.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes and genotype-phenotype correlations in patients with complete and partial androgen insensitivity syndromes. 完全和部分雄激素不敏感综合征患者的临床结果和基因型-表型相关性。
IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 Epub Date: 2023-02-01 DOI: 10.6065/apem.2244152.076
Nae-Yun Lee, Ja Hye Kim, Ji-Hee Yoon, Soojin Hwang, Gu-Hwan Kim, Han-Wook Yoo, Jin-Ho Choi

Purpose: Androgen insensitivity syndrome (AIS) is a rare X-linked recessive disorder caused by unresponsiveness to androgens because of mutations in the AR gene. Here, we investigated the clinical outcomes and molecular spectrum of AR variants in patients with AIS attending a single academic center.

Methods: This study included 19 patients with AIS who were confirmed by molecular analysis of AR. Clinical features and endocrinological findings were retrospectively collected, including presenting features, external genitalia, sex of rearing, timing of gonadectomy, pubertal outcomes, and sex hormone levels. Molecular analysis of AR was performed using Sanger, targeted gene panel, or whole-exome sequencing.

Results: Among all 19 patients, 14 (74%) were classified as having complete AIS (CAIS), whereas 5 (26%) had partial AIS (PAIS). All patients with CAIS, and 3 patients with PAIS were reared as female. One patient with CAIS manifested a mixed germ cell tumor at the age of 30 years. Molecular analysis of AR identified 19 sequence variants; 12 (63%) were previously reported, and the remaining 7 (37%) were novel. Missense mutations were the most common type (12 of 19, 63%), followed by small deletions, nonsense mutations, an insertion, and a splice site mutation.

Conclusion: Here, we describe the clinical outcomes and molecular characteristics of 19 Korean patients with AIS. Patients with PAIS manifested various degrees of masculinization of the external genitalia. Nonsense and frameshift mutations were frequent in patients with CAIS, whereas patients with PAIS harbored exclusively missense mutations.

目的:雄激素不敏感综合征(AIS)是一种罕见的X连锁隐性疾病,由AR基因突变引起的对雄激素无反应引起。在这里,我们研究了在单一学术中心就诊的AIS患者的临床结果和AR变体的分子谱。方法:本研究纳入了19例经AR分子分析证实的AIS患者。回顾性收集临床特征和内分泌结果,包括表现特征、外生殖器、养育性别、性腺切除时间、青春期结局和性激素水平。AR的分子分析使用Sanger、靶向基因组或全外显子组测序进行。结果:在所有19例患者中,14例(74%)被归类为完全性AIS(CAIS),而5例(26%)患有部分性AIS(PAIS)。所有CAIS患者和3例PAIS患者均为女性。一名CAIS患者在30岁时表现为混合生殖细胞肿瘤。AR的分子分析鉴定了19个序列变体;12个(63%)是先前报道的,其余7个(37%)是新的。错义突变是最常见的类型(19个中有12种,63%),其次是小缺失、无义突变、插入和剪接位点突变。结论:在这里,我们描述了19名韩国AIS患者的临床结果和分子特征。PAIS患者外生殖器表现出不同程度的男性化。在CAIS患者中,无义和移码突变是常见的,而PAIS患者仅携带错义突变。
{"title":"Clinical outcomes and genotype-phenotype correlations in patients with complete and partial androgen insensitivity syndromes.","authors":"Nae-Yun Lee,&nbsp;Ja Hye Kim,&nbsp;Ji-Hee Yoon,&nbsp;Soojin Hwang,&nbsp;Gu-Hwan Kim,&nbsp;Han-Wook Yoo,&nbsp;Jin-Ho Choi","doi":"10.6065/apem.2244152.076","DOIUrl":"10.6065/apem.2244152.076","url":null,"abstract":"<p><strong>Purpose: </strong>Androgen insensitivity syndrome (AIS) is a rare X-linked recessive disorder caused by unresponsiveness to androgens because of mutations in the AR gene. Here, we investigated the clinical outcomes and molecular spectrum of AR variants in patients with AIS attending a single academic center.</p><p><strong>Methods: </strong>This study included 19 patients with AIS who were confirmed by molecular analysis of AR. Clinical features and endocrinological findings were retrospectively collected, including presenting features, external genitalia, sex of rearing, timing of gonadectomy, pubertal outcomes, and sex hormone levels. Molecular analysis of AR was performed using Sanger, targeted gene panel, or whole-exome sequencing.</p><p><strong>Results: </strong>Among all 19 patients, 14 (74%) were classified as having complete AIS (CAIS), whereas 5 (26%) had partial AIS (PAIS). All patients with CAIS, and 3 patients with PAIS were reared as female. One patient with CAIS manifested a mixed germ cell tumor at the age of 30 years. Molecular analysis of AR identified 19 sequence variants; 12 (63%) were previously reported, and the remaining 7 (37%) were novel. Missense mutations were the most common type (12 of 19, 63%), followed by small deletions, nonsense mutations, an insertion, and a splice site mutation.</p><p><strong>Conclusion: </strong>Here, we describe the clinical outcomes and molecular characteristics of 19 Korean patients with AIS. Patients with PAIS manifested various degrees of masculinization of the external genitalia. Nonsense and frameshift mutations were frequent in patients with CAIS, whereas patients with PAIS harbored exclusively missense mutations.</p>","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":" ","pages":"184-192"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/33/c9/apem-2244152-076.PMC10556439.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9195129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between short stature at 3 years old and height, weight, and body mass index changes for 6 years after birth: a retrospective, nationwide, population-based study of children born 2011-2014 in Korea. 3岁时身材矮小与出生后6年身高、体重和体重指数变化之间的关系:一项针对2011-2014年韩国出生儿童的全国性回顾性人群研究。
IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 Epub Date: 2023-02-03 DOI: 10.6065/apem.2244190.095
Seo Jung Kim, Ju Hyun Jin, In Hyuk Chung

Purpose: Height at 3 years of age, when catch-up growth based on birth history is completed, is considered a major prognostic factor for predicting short stature, underweight, and growth faltering. However, too few large-scale studies have followed and analyzed height, weight, and body mass index (BMI) changes in children whose stature was short at 3 years of age. This study followed and compared the growth parameters (height, weight, and BMI) of children with short stature at 3 years of age and children with nonshort stature at 3 years of age for 6 years after birth using nationwide, population-based data.

Methods: We retrospectively analyzed physical measurement data from the National Health Screening Program for Infants and Children for people born in 2011-2014 in Korea and followed to 2020. The data were provided by the National Health Insurance Service's customized data service. Growth parameters were compared using chi-square tests, Student t-tests, analyses of variance, and linear regressions.

Results: Among 210,902 enrolled participants, 759 (0.4%) and 210,143 (99.6%) were in the short stature at 3 years group and the nonshort stature at 3 years group, respectively. In both sexes, height, weight, and BMI for 6 years after birth were significantly higher in the nonshort stature at 3 years group than in the short stature at 3 years group (P<0.0001). The BMI rebound was observed later than the standard period in the short stature at 3 years group.

Conclusion: Early intervention and close follow-up are necessary to prevent persistent short stature and growth faltering in children with short stature at 3 years of age.

目的:3岁时的身高,当根据出生史完成追赶性生长时,被认为是预测身材矮小、体重不足和生长迟缓的主要预后因素。然而,很少有大规模研究跟踪和分析3岁时身材矮小儿童的身高、体重和体重指数(BMI)变化。本研究使用全国范围的基于人群的数据,跟踪并比较了3岁时身材矮小的儿童和3岁时出生后6年的非身材矮小儿童的生长参数(身高、体重和BMI)。方法:我们回顾性分析了韩国2011-2014年出生并随访至2020年的国家婴幼儿健康筛查计划的身体测量数据。这些数据是由国家健康保险局的定制数据服务提供的。使用卡方检验、Student t检验、方差分析和线性回归对生长参数进行比较。结果:在210902名入选参与者中,759名(0.4%)和210143名(99.6%)分别属于3岁时身材矮小组和3岁时非身材矮小组。在两性中,3岁时非身材矮小组出生后6年的身高、体重和BMI均显著高于3岁时身材矮小组(P结论:早期干预和密切随访是必要的,以防止3岁时身高矮小儿童持续性身材矮小和生长迟缓。
{"title":"Relationship between short stature at 3 years old and height, weight, and body mass index changes for 6 years after birth: a retrospective, nationwide, population-based study of children born 2011-2014 in Korea.","authors":"Seo Jung Kim,&nbsp;Ju Hyun Jin,&nbsp;In Hyuk Chung","doi":"10.6065/apem.2244190.095","DOIUrl":"10.6065/apem.2244190.095","url":null,"abstract":"<p><strong>Purpose: </strong>Height at 3 years of age, when catch-up growth based on birth history is completed, is considered a major prognostic factor for predicting short stature, underweight, and growth faltering. However, too few large-scale studies have followed and analyzed height, weight, and body mass index (BMI) changes in children whose stature was short at 3 years of age. This study followed and compared the growth parameters (height, weight, and BMI) of children with short stature at 3 years of age and children with nonshort stature at 3 years of age for 6 years after birth using nationwide, population-based data.</p><p><strong>Methods: </strong>We retrospectively analyzed physical measurement data from the National Health Screening Program for Infants and Children for people born in 2011-2014 in Korea and followed to 2020. The data were provided by the National Health Insurance Service's customized data service. Growth parameters were compared using chi-square tests, Student t-tests, analyses of variance, and linear regressions.</p><p><strong>Results: </strong>Among 210,902 enrolled participants, 759 (0.4%) and 210,143 (99.6%) were in the short stature at 3 years group and the nonshort stature at 3 years group, respectively. In both sexes, height, weight, and BMI for 6 years after birth were significantly higher in the nonshort stature at 3 years group than in the short stature at 3 years group (P<0.0001). The BMI rebound was observed later than the standard period in the short stature at 3 years group.</p><p><strong>Conclusion: </strong>Early intervention and close follow-up are necessary to prevent persistent short stature and growth faltering in children with short stature at 3 years of age.</p>","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":" ","pages":"193-199"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/34/apem-2244190-095.PMC10556449.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9238297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel variant of THRβ and its 4-year clinical course in a Korean boy with resistance to thyroid hormone. 一名对甲状腺激素有耐药性的韩国男孩的THRβ新变体及其4年临床过程。
IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 Epub Date: 2023-09-19 DOI: 10.6065/apem.2142246.123
Sejin Kim, Soyun Park, Jungeun Moon, Heungsik Kim, Seokjin Kang

Thyroid hormone resistance (RTH) is characterized by a decreased sensitivity of target tissues to thyroid hormones due to a defect in the THRα- and THRβ-encoded thyroid hormone receptors (THRs). The clinical manifestations range from no symptoms to simple goiter and hypo- or hyperthyroidism, depending on the receptor subtype distribution in the tissues. Here, we report the case of a thyroid hormone-resistant 12-month-old boy carrying a novel THRβ variant who was initially diagnosed with congenital hypothyroidism. An extensive evaluation revealed increased free T4 level and inappropriately increased thyroid-stimulating hormone (TSH) level; a normal lipid profile, sex hormone-binding globulin, and free alpha subunit of TSH; exaggerated TSH response to THR; and no radiological evidence of pituitary adenoma. A targeted next-generation sequencing panel identified a heterozygote c.993T>G (p.Asn331Lys) mutation in the THRβ gene. During the first year of life, a higher dose of levothyroxine was administered to the patient due to uncompensated RTH. Levothyroxine treatment was continued after 3 years to maintain TSH level <5 mIU/mL, but the observed weight gain was poor, height increase was insufficient, and bone development was delayed. However, neither hyperactivity nor developmental delay was observed. Patients with RTH exhibit various clinical features. Due to its heterogeneous nature, genetic test for accurate diagnosis is important to provide proper management.

甲状腺激素抵抗(RTH)的特征是由于THRα和THRβ编码的甲状腺激素受体(THRs)的缺陷,靶组织对甲状腺激素的敏感性降低。根据受体亚型在组织中的分布,临床表现从无症状到单纯甲状腺肿、甲状腺功能减退或甲状腺功能亢进不等。在这里,我们报告了一例甲状腺激素抵抗的12个月大男孩携带一种新的THRβ变体,最初被诊断为先天性甲状腺功能减退症。一项广泛的评估显示,游离T4水平升高,促甲状腺激素(TSH)水平不适当升高;正常的脂质图谱、性激素结合球蛋白和TSH的游离α亚基;TSH对THR反应过度;并且没有垂体腺瘤的放射学证据。一个有针对性的下一代测序小组在THRβ基因中发现了一个杂合子c.993T>G(p.Asn331Lys)突变。在患者生命的第一年,由于RTH未得到补偿,患者服用了更高剂量的左甲状腺素。3年后继续左甲状腺素治疗以维持TSH水平
{"title":"A novel variant of THRβ and its 4-year clinical course in a Korean boy with resistance to thyroid hormone.","authors":"Sejin Kim,&nbsp;Soyun Park,&nbsp;Jungeun Moon,&nbsp;Heungsik Kim,&nbsp;Seokjin Kang","doi":"10.6065/apem.2142246.123","DOIUrl":"10.6065/apem.2142246.123","url":null,"abstract":"<p><p>Thyroid hormone resistance (RTH) is characterized by a decreased sensitivity of target tissues to thyroid hormones due to a defect in the THRα- and THRβ-encoded thyroid hormone receptors (THRs). The clinical manifestations range from no symptoms to simple goiter and hypo- or hyperthyroidism, depending on the receptor subtype distribution in the tissues. Here, we report the case of a thyroid hormone-resistant 12-month-old boy carrying a novel THRβ variant who was initially diagnosed with congenital hypothyroidism. An extensive evaluation revealed increased free T4 level and inappropriately increased thyroid-stimulating hormone (TSH) level; a normal lipid profile, sex hormone-binding globulin, and free alpha subunit of TSH; exaggerated TSH response to THR; and no radiological evidence of pituitary adenoma. A targeted next-generation sequencing panel identified a heterozygote c.993T>G (p.Asn331Lys) mutation in the THRβ gene. During the first year of life, a higher dose of levothyroxine was administered to the patient due to uncompensated RTH. Levothyroxine treatment was continued after 3 years to maintain TSH level <5 mIU/mL, but the observed weight gain was poor, height increase was insufficient, and bone development was delayed. However, neither hyperactivity nor developmental delay was observed. Patients with RTH exhibit various clinical features. Due to its heterogeneous nature, genetic test for accurate diagnosis is important to provide proper management.</p>","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"28 3","pages":"219-224"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5b/d9/apem-2142246-123.PMC10556442.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41177245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypoparathyroidism in children and adolescents. 儿童和青少年的甲状旁腺功能减退症。
IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 Epub Date: 2023-09-19 DOI: 10.6065/apem.2346096.048
Hüseyin Anıl Korkmaz, Behzat Ozkan

Hypoparathyroidism is characterized by insufficient parathyroid hormone (PTH) release from the parathyroid glands to maintain serum calcium level within normal limits and unresponsiveness of target tissues despite normal serum PTH level. Hypoparathyroidism is defined as low or inappropriately normal serum PTH level. In this narrative review, we discuss the etiology of hypoparathyroidism in children.

甲状旁腺功能减退症的特征是甲状旁腺释放的甲状旁腺激素(PTH)不足,无法将血清钙水平维持在正常范围内,尽管血清PTH水平正常,但靶组织无反应。甲状旁腺功能减退症是指血清甲状旁腺激素水平低或异常正常。在这篇叙述性综述中,我们讨论了儿童甲状旁腺功能减退症的病因。
{"title":"Hypoparathyroidism in children and adolescents.","authors":"Hüseyin Anıl Korkmaz,&nbsp;Behzat Ozkan","doi":"10.6065/apem.2346096.048","DOIUrl":"10.6065/apem.2346096.048","url":null,"abstract":"<p><p>Hypoparathyroidism is characterized by insufficient parathyroid hormone (PTH) release from the parathyroid glands to maintain serum calcium level within normal limits and unresponsiveness of target tissues despite normal serum PTH level. Hypoparathyroidism is defined as low or inappropriately normal serum PTH level. In this narrative review, we discuss the etiology of hypoparathyroidism in children.</p>","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"28 3","pages":"159-167"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/d3/apem-2346096-048.PMC10556444.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41132946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents. 2022年韩国儿童和青少年中枢性早熟临床实践指南。
IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 Epub Date: 2023-09-19 DOI: 10.6065/apem.2346168.084
Su Jin Kim, Ji Hyun Kim, Yong Hee Hong, In Hyuk Chung, Eun Byoul Lee, Eungu Kang, Jinsup Kim, Aram Yang, Young-Jun Rhie, Eun-Gyong Yoo, Young-Lim Shin, Jin Ho Choi, Soo Young Kim, Jieun Lee

The Committee of Central Precocious Puberty of Korean Pediatrics and Adolescents of the Korean Society of Pediatric Endocrinology has newly developed evidence-based 2022 clinical practice guidelines for central precocious puberty in Korean children and adolescents. These guidelines provide the grade of recommendations, which includes both the strength of recommendations and the level of evidence. In the absence of sufficient evidence, recommendations are based on expert opinion. These guidelines have been revised and supplement the previous guidelines "Clinical Guidelines for Precocious Puberty 2011," and are drawn from a comprehensive review of the latest domestic and international research and the grade of recommendation appropriate to the domestic situation. This review summarizes the newly revised guidelines into 8 key questions and 27 recommendations and consists of 4 sections: screening, diagnosis, treatment, and long-term outcome of central precocious puberty.

韩国儿科内分泌学学会的韩国儿科和青少年中枢性早熟委员会最新制定了基于证据的2022年韩国儿童青少年中枢性性早熟临床实践指南。这些准则规定了建议的等级,其中包括建议的强度和证据水平。在缺乏充分证据的情况下,建议是根据专家意见提出的。这些指南对之前的指南“2011年性早熟临床指南”进行了修订和补充,并根据对国内外最新研究和适合国内情况的推荐等级的全面审查得出。这篇综述将新修订的指南总结为8个关键问题和27条建议,包括4个部分:中枢性性早熟的筛查、诊断、治疗和长期结果。
{"title":"2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents.","authors":"Su Jin Kim,&nbsp;Ji Hyun Kim,&nbsp;Yong Hee Hong,&nbsp;In Hyuk Chung,&nbsp;Eun Byoul Lee,&nbsp;Eungu Kang,&nbsp;Jinsup Kim,&nbsp;Aram Yang,&nbsp;Young-Jun Rhie,&nbsp;Eun-Gyong Yoo,&nbsp;Young-Lim Shin,&nbsp;Jin Ho Choi,&nbsp;Soo Young Kim,&nbsp;Jieun Lee","doi":"10.6065/apem.2346168.084","DOIUrl":"10.6065/apem.2346168.084","url":null,"abstract":"<p><p>The Committee of Central Precocious Puberty of Korean Pediatrics and Adolescents of the Korean Society of Pediatric Endocrinology has newly developed evidence-based 2022 clinical practice guidelines for central precocious puberty in Korean children and adolescents. These guidelines provide the grade of recommendations, which includes both the strength of recommendations and the level of evidence. In the absence of sufficient evidence, recommendations are based on expert opinion. These guidelines have been revised and supplement the previous guidelines \"Clinical Guidelines for Precocious Puberty 2011,\" and are drawn from a comprehensive review of the latest domestic and international research and the grade of recommendation appropriate to the domestic situation. This review summarizes the newly revised guidelines into 8 key questions and 27 recommendations and consists of 4 sections: screening, diagnosis, treatment, and long-term outcome of central precocious puberty.</p>","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"28 3","pages":"168-177"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/5e/apem-2346168-084.PMC10556443.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41166705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The effect of hypothalamic involvement and growth hormone treatment on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma. 下丘脑受损伤及生长激素治疗对儿童期颅咽管瘤患者心血管危险因素的影响
IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-06-01 DOI: 10.6065/apem.2244046.023
Sang Hee Park, Yun Jeong Lee, Jung-Eun Cheon, Choong Ho Shin, Haewoon Jung, Young Ah Lee

Purpose: Hypothalamic damage may increase the risk of adulthood obesity and cardiovascular disease in patients with craniopharyngioma. We evaluated the effects of hypothalamic involvement (HI) and growth hormone (GH) discontinuation on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma.

Methods: Thirty-three patients (17 males, 16 females) underwent retesting for adult GH deficiency (GHD) between 2005 and 2020 at Seoul National University Children's Hospital. Postoperative HI was graded by Puget's criteria and data regarding GH replacement were collected. At retesting, body mass index (BMI), fasting blood glucose, insulin, high-density lipoprotein cholesterol (HDL-C), triglycerides, and blood pressure were assessed.

Results: The mean age of commencement and discontinuation of GH replacement for childhood GHD was 10.0±3.6 and 15.3±3.1 years, respectively. The mean age at retesting for adult GHD was 17.7±2.5 years. When patients were categorized by post-GH discontinuation duration, those with durations >6 months (n=27) showed lower HDL-C levels than those with <6 months (P=0.037). Patients with extensive HI (n=16) had higher BMI z-scores than did those with no HI or mild HI (P=0.020). Both the extent of HI and longer post-GH discontinuation duration were significantly predictive for decreased HDL-C levels (P<0.05, for both).

Conclusion: The extent of HI and GH discontinuation duration during the transition period can increase cardiovascular risks in patients with childhood-onset craniopharyngioma.

目的:下丘脑损伤可能增加颅咽管瘤患者成年期肥胖和心血管疾病的风险。我们评估了下丘脑受损伤(HI)和生长激素(GH)停药对儿童期颅咽管瘤患者心血管危险因素的影响。方法:2005年至2020年间,33名患者(17名男性,16名女性)在首尔国立大学儿童医院接受了成人生长激素缺乏症(GHD)的重新检测。术后HI按照Puget标准分级,并收集GH置换数据。在重新测试时,评估体重指数(BMI)、空腹血糖、胰岛素、高密度脂蛋白胆固醇(HDL-C)、甘油三酯和血压。结果:儿童GHD开始和停止GH替代治疗的平均年龄分别为10.0±3.6岁和15.3±3.1岁。成人GHD复诊的平均年龄为17.7±2.5岁。根据GH停药后持续时间对患者进行分类时,持续时间>6个月的患者(n=27) HDL-C水平低于持续停药6个月的患者。结论:过渡时期HI和GH停药时间的长短可增加儿童期颅咽管瘤患者的心血管风险。
{"title":"The effect of hypothalamic involvement and growth hormone treatment on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma.","authors":"Sang Hee Park,&nbsp;Yun Jeong Lee,&nbsp;Jung-Eun Cheon,&nbsp;Choong Ho Shin,&nbsp;Haewoon Jung,&nbsp;Young Ah Lee","doi":"10.6065/apem.2244046.023","DOIUrl":"https://doi.org/10.6065/apem.2244046.023","url":null,"abstract":"<p><strong>Purpose: </strong>Hypothalamic damage may increase the risk of adulthood obesity and cardiovascular disease in patients with craniopharyngioma. We evaluated the effects of hypothalamic involvement (HI) and growth hormone (GH) discontinuation on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma.</p><p><strong>Methods: </strong>Thirty-three patients (17 males, 16 females) underwent retesting for adult GH deficiency (GHD) between 2005 and 2020 at Seoul National University Children's Hospital. Postoperative HI was graded by Puget's criteria and data regarding GH replacement were collected. At retesting, body mass index (BMI), fasting blood glucose, insulin, high-density lipoprotein cholesterol (HDL-C), triglycerides, and blood pressure were assessed.</p><p><strong>Results: </strong>The mean age of commencement and discontinuation of GH replacement for childhood GHD was 10.0±3.6 and 15.3±3.1 years, respectively. The mean age at retesting for adult GHD was 17.7±2.5 years. When patients were categorized by post-GH discontinuation duration, those with durations >6 months (n=27) showed lower HDL-C levels than those with <6 months (P=0.037). Patients with extensive HI (n=16) had higher BMI z-scores than did those with no HI or mild HI (P=0.020). Both the extent of HI and longer post-GH discontinuation duration were significantly predictive for decreased HDL-C levels (P<0.05, for both).</p><p><strong>Conclusion: </strong>The extent of HI and GH discontinuation duration during the transition period can increase cardiovascular risks in patients with childhood-onset craniopharyngioma.</p>","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"28 2","pages":"107-115"},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/f8/apem-2244046-023.PMC10329945.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9771367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 207
Molecular basis and genetic testing strategies for diagnosing 21-hydroxylase deficiency, including CAH-X syndrome. 诊断21-羟化酶缺乏症的分子基础和基因检测策略,包括CAH-X综合征。
IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-06-01 DOI: 10.6065/apem.2346108.054
Ja Hye Kim, Gu-Hwan Kim, Han-Wook Yoo, Jin-Ho Choi

Congenital adrenal hyperplasia (CAH) is a group of autosomally recessive disorders that result from impaired synthesis of glucocorticoid and mineralocorticoid. Most cases (~95%) are caused by mutations in the CYP21A2 gene, which encodes steroid 21-hydroxylase. CAH patients manifest a wide phenotypic spectrum according to their degree of residual enzyme activity. CYP21A2 and its pseudogene (CYP21A1P) are located 30 kb apart in the 6q21.3 region and share approximately 98% of their sequences in the coding region. Both genes are aligned in tandem with the C4, SKT19, and TNX genes, forming 2 segments of the RCCX modules that are arranged as STK19-C4A-CYP21A1P-TNXA-STK19B-C4B-CYP21A2-TNXB. The high sequence homology between the active gene and pseudogene leads to frequent microconversions and large rearrangements through intergenic recombination. The TNXB gene encodes an extracellular matrix glycoprotein, tenascin-X (TNX), and defects in TNXB cause Ehlers-Danlos syndrome. Deletions affecting both CYP21A2 and TNXB result in a contiguous gene deletion syndrome known as CAH-X syndrome. Because of the high homology between CYP21A2 and CYP21A1P, genetic testing for CAH should include an evaluation of copy number variations, as well as Sanger sequencing. Although it poses challenges for genetic testing, a large number of mutations and their associated phenotypes have been identified, which has helped to establish genotype-phenotype correlations. The genotype is helpful for guiding early treatment, predicting the clinical phenotype and prognosis, and providing genetic counseling. In particular, it can help ensure proper management of the potential complications of CAH-X syndrome, such as musculoskeletal and cardiac defects. This review focuses on the molecular pathophysiology and genetic diagnosis of 21-hydroxylase deficiency and highlights genetic testing strategies for CAH-X syndrome.

先天性肾上腺皮质增生症(CAH)是一组常染色体隐性疾病,由糖皮质激素和矿皮质激素合成受损引起。大多数病例(约95%)是由编码类固醇21-羟化酶的CYP21A2基因突变引起的。CAH患者根据其残余酶活性的程度表现出广泛的表型谱。CYP21A2及其假基因(CYP21A1P)位于6q21.3区域,相距30 kb,在编码区共享约98%的序列。这两个基因与C4、SKT19和TNX基因串联排列,形成RCCX模块的2个片段,排列为STK19-C4A-CYP21A1P-TNXA-STK19B-C4B-CYP21A2-TNXB。活性基因和假基因之间的高度同源性导致基因间重组导致频繁的微转换和大量重排。TNXB基因编码细胞外基质糖蛋白tenascin-X (TNX), TNXB基因缺陷导致ehers - danlos综合征。影响CYP21A2和TNXB的缺失导致一种称为CAH-X综合征的连续基因缺失综合征。由于CYP21A2和CYP21A1P之间的高度同源性,CAH的基因检测应包括拷贝数变异的评估,以及Sanger测序。尽管这给基因检测带来了挑战,但大量的突变及其相关表型已被确定,这有助于建立基因型-表型相关性。基因型有助于指导早期治疗,预测临床表型和预后,提供遗传咨询。特别是,它可以帮助确保适当管理CAH-X综合征的潜在并发症,如肌肉骨骼和心脏缺陷。本文综述了21-羟化酶缺乏症的分子病理生理和遗传学诊断,并重点介绍了CAH-X综合征的基因检测策略。
{"title":"Molecular basis and genetic testing strategies for diagnosing 21-hydroxylase deficiency, including CAH-X syndrome.","authors":"Ja Hye Kim,&nbsp;Gu-Hwan Kim,&nbsp;Han-Wook Yoo,&nbsp;Jin-Ho Choi","doi":"10.6065/apem.2346108.054","DOIUrl":"https://doi.org/10.6065/apem.2346108.054","url":null,"abstract":"<p><p>Congenital adrenal hyperplasia (CAH) is a group of autosomally recessive disorders that result from impaired synthesis of glucocorticoid and mineralocorticoid. Most cases (~95%) are caused by mutations in the CYP21A2 gene, which encodes steroid 21-hydroxylase. CAH patients manifest a wide phenotypic spectrum according to their degree of residual enzyme activity. CYP21A2 and its pseudogene (CYP21A1P) are located 30 kb apart in the 6q21.3 region and share approximately 98% of their sequences in the coding region. Both genes are aligned in tandem with the C4, SKT19, and TNX genes, forming 2 segments of the RCCX modules that are arranged as STK19-C4A-CYP21A1P-TNXA-STK19B-C4B-CYP21A2-TNXB. The high sequence homology between the active gene and pseudogene leads to frequent microconversions and large rearrangements through intergenic recombination. The TNXB gene encodes an extracellular matrix glycoprotein, tenascin-X (TNX), and defects in TNXB cause Ehlers-Danlos syndrome. Deletions affecting both CYP21A2 and TNXB result in a contiguous gene deletion syndrome known as CAH-X syndrome. Because of the high homology between CYP21A2 and CYP21A1P, genetic testing for CAH should include an evaluation of copy number variations, as well as Sanger sequencing. Although it poses challenges for genetic testing, a large number of mutations and their associated phenotypes have been identified, which has helped to establish genotype-phenotype correlations. The genotype is helpful for guiding early treatment, predicting the clinical phenotype and prognosis, and providing genetic counseling. In particular, it can help ensure proper management of the potential complications of CAH-X syndrome, such as musculoskeletal and cardiac defects. This review focuses on the molecular pathophysiology and genetic diagnosis of 21-hydroxylase deficiency and highlights genetic testing strategies for CAH-X syndrome.</p>","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"28 2","pages":"77-86"},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/b9/apem-2346108-054.PMC10329939.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9767021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A case of maturity-onset diabetes of the young type 4 in Korea. 韩国青少年4型成熟型糖尿病1例。
IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-06-01 DOI: 10.6065/apem.2142188.094
Geu-Meum Park, Soo Jung Lee, Ja Young Seo, Kyung In Lim
Maturity-onset diabetes of the young (MODY) is a rare, autosomal dominant disease characterized by non-ketogenic diabetes mellitus (DM). MODY type 4, caused by PDX1 mutation, is a very rare subtype of MODY, especially in Korea. We report a case of a 10-year-old, nonobese girl with a family history of type 2 DM. After diagnosis, the patient’s serum glucose level was well controlled using metformin monotherapy; however, the glycated hemoglobin level increased to 9.0% approximately 2 years after treatment. No obesity or lifestyle problems were observed, and serum fasting C-peptide level was within the normal range. Furthermore, no islet-related autoantibodies were detected. A genetic screening for MODY using a next-generation sequencing panel was performed, and a likely heterozygous pathogenic PDX1 mutation (p.Gly246ArgfsTer21) was identified. The PDX1 variant was not detected in her mother, implying that the mutation had arisen de novo in the proband. She was prescribed insulin degludec in addition to metformin therapy, which improved her hyperglycemia. This report presents a novel MODY type 4 phenotype and highlights the importance of genetic screening in patients with MODY characteristics.
青年成熟型糖尿病(MODY)是一种罕见的常染色体显性疾病,以非生酮性糖尿病(DM)为特征。由PDX1突变引起的MODY 4型是一种非常罕见的MODY亚型,特别是在韩国。我们报告一例10岁的非肥胖女孩,有2型糖尿病家族史。诊断后,患者的血清葡萄糖水平得到很好的控制,使用二甲双胍单药治疗;然而,治疗后约2年糖化血红蛋白水平上升至9.0%。无肥胖或生活方式问题,血清空腹c肽水平在正常范围内。此外,未检测到胰岛相关自身抗体。使用下一代测序面板对MODY进行遗传筛选,鉴定出可能的杂合致病性PDX1突变(p.Gly246ArgfsTer21)。在她的母亲身上没有检测到PDX1变异,这意味着该突变是在先证者身上从头开始的。在二甲双胍治疗的基础上,医生给她开了降糖糖胰岛素,这改善了她的高血糖。本报告提出了一种新的MODY 4型表型,并强调了在具有MODY特征的患者中进行遗传筛查的重要性。
{"title":"A case of maturity-onset diabetes of the young type 4 in Korea.","authors":"Geu-Meum Park,&nbsp;Soo Jung Lee,&nbsp;Ja Young Seo,&nbsp;Kyung In Lim","doi":"10.6065/apem.2142188.094","DOIUrl":"https://doi.org/10.6065/apem.2142188.094","url":null,"abstract":"Maturity-onset diabetes of the young (MODY) is a rare, autosomal dominant disease characterized by non-ketogenic diabetes mellitus (DM). MODY type 4, caused by PDX1 mutation, is a very rare subtype of MODY, especially in Korea. We report a case of a 10-year-old, nonobese girl with a family history of type 2 DM. After diagnosis, the patient’s serum glucose level was well controlled using metformin monotherapy; however, the glycated hemoglobin level increased to 9.0% approximately 2 years after treatment. No obesity or lifestyle problems were observed, and serum fasting C-peptide level was within the normal range. Furthermore, no islet-related autoantibodies were detected. A genetic screening for MODY using a next-generation sequencing panel was performed, and a likely heterozygous pathogenic PDX1 mutation (p.Gly246ArgfsTer21) was identified. The PDX1 variant was not detected in her mother, implying that the mutation had arisen de novo in the proband. She was prescribed insulin degludec in addition to metformin therapy, which improved her hyperglycemia. This report presents a novel MODY type 4 phenotype and highlights the importance of genetic screening in patients with MODY characteristics.","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"28 2","pages":"149-154"},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/35/apem-2142188-094.PMC10329942.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9759290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Annals of Pediatric Endocrinology & Metabolism
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1